National Medical Services, Inc.

National Medical Services, Inc., doing business as NMS Labs, is a Horsham, Pennsylvania-based clinical and forensic laboratory services provider competing as a prime contractor in the full-and-open federal market, with expertise in forensic toxicology testing, neurobiobank tissue analysis, and expert witness testimony supporting federal law enforcement, research, and judicial proceedings. The company operates across medical laboratories (NAICS 621511) and legal services (NAICS 541900 series), with a thirty-year federal contracting track record dating to 1996 and over fifty years of operational history in forensic science.

NMS Labs' customer concentration is heavily weighted toward Department of Justice litigation support and National Institutes of Health research funding. The Department of Justice Offices Boards and Divisions US Attorney's Offices account for 68 awards but only $323 thousand in combined potential value—a high-volume, low-dollar pattern driven by time-and-materials expert witness purchase orders supporting individual criminal prosecutions. By contrast, the Department of Health and Human Services' National Institute on Drug Abuse (NIDA) anchors the dollar base with 35 awards worth $9.4 million combined potential value, followed by the DOJ Criminal Division (3 awards, $6.7 million), the National Institute of Mental Health (4 awards, $3 million), and Veterans Health Administration networks. Together, the top five customer agencies by potential value represent approximately 60% of the combined $33.6 million across all awards.

NMS Labs holds two significant IDCs: a $3 million indefinite delivery contract with NIDA (awarded September 27, 2024, ceiling through September 26, 2028) for neurobiobank tissue toxicology testing services supporting NIMH's mental health research programs, and a $240 thousand Blanket Purchase Agreement with the Defense Health Agency (awarded March 24, 2026, ceiling through March 23, 2031) for American Board of Forensic Toxicology (ABFT) or ISO forensic toxicology testing. Recent work under the NIDA IDC includes a $549,092 delivery order (September 2024) and a $574,984 delivery order (August 2026) for toxicological analysis of post-mortem brain tissue, blood, and hair to detect therapeutic drugs, drugs of abuse, and environmental toxins. A $416,775 firm fixed-price purchase order from the CSOSA Pretrial Services Agency (September 2025 through September 2030) calls for urine and oral fluid confirmation testing in Washington, DC. Expert witness work spans the U.S. Attorney's Offices across multiple districts, with individual purchase orders typically in the $5,000 to $40,000 range on time-and-materials terms, representing support for federal criminal prosecution.

Activity has declined moderately year over year—fourteen awards in 2022 down to six in both 2025 and 2026 to date—though the dollar magnitude has shifted toward larger research and testing IDCs rather than small expert witness orders. Eight awards carrying combined potential value of $651 thousand face ultimate completion within the next twenty-four months. NMS Labs' subcontractor footprint is minimal; the source names a single sub-award to Battelle Memorial Institute (June 2025) for ongoing force health protection analysis and PFAS serum/plasma lab analysis supporting the Navy and Marine Corps Public Health Center. The vendor's PSC profile splits between reference laboratory testing (73 awards) and expert witness support (71 awards), with the laboratory testing portfolio dominating recent dollar value and growth trajectory.